RESUMEN
Testing of blood sera of 63 hemophiliacs revealed markers of hepatitides B and C in 97 and 98% cases, respectively. Polymerase chain reaction confirmed the presence of hepatitis C virus (HCV) RNA in 31 (94%) out of 33 sera tested which contained antibodies to HCV. Gene typing of the isolated strains revealed the presence of three types of HCV: 1b (94%), 2a (3%), and 3a (3%). Similar distribution of HCV genotypes was revealed in the blood sera of 39 patients with chronic hepatitis C.
Asunto(s)
Genotipo , Hemofilia A/complicaciones , Hepacivirus/genética , Hepatitis C/complicaciones , Enfermedad Crónica , Hepacivirus/clasificación , Hepacivirus/aislamiento & purificación , Anticuerpos contra la Hepatitis C/sangre , Humanos , Técnicas para Inmunoenzimas , Reacción en Cadena de la Polimerasa , ARN Viral/sangreRESUMEN
The study was performed of clinico-biochemical effect of plasmapheresis (PA) in severe viral hepatitis B, mixed hepatitis and hepatitis delta. Altogether 24 patients, all of them HBsAg carriers, were examined. With associated acute hepatic encephalopathy, clinical effect in hepatitis of PA was insignificant notwithstanding positive biochemical changes. In the absence of hepatic encephalopathy PA effect was pronounced both clinically and biochemically.
Asunto(s)
Encefalopatía Hepática/terapia , Hepatitis B/terapia , Hepatitis D/terapia , Hígado/metabolismo , Plasmaféresis , Adolescente , Adulto , Anciano , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Bilirrubina/sangre , Niño , Encefalopatía Hepática/etiología , Encefalopatía Hepática/metabolismo , Hepatitis B/complicaciones , Hepatitis B/metabolismo , Hepatitis D/complicaciones , Hepatitis D/metabolismo , Humanos , Lipoproteínas LDL/sangre , Persona de Mediana EdadRESUMEN
Clinical, biochemical and serological examinations of 412 patients with acute HBsAg-positive virus hepatitis were conducted to assess therapeutic efficacy of Soviet recombinant alpha 2-interferon (reaferon). There were 309 cases of acute virus hepatitis B, 103 of delta infection (71--coinfection, 32--superinfection). The study and control groups were assigned randomly. Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days. The treatment proved effective in acute hepatitis B running a moderately severe and severe course up to the development of acute hepatic encephalopathy. In delta infection reaferon produced response in coinfection only. In fulminant hepatitis the treatment was uneffective.
Asunto(s)
Hepatitis B/terapia , Hepatitis D/terapia , Interferón Tipo I/uso terapéutico , Enfermedad Aguda , Adolescente , Adulto , Anciano , Evaluación de Medicamentos , Hepatitis B/complicaciones , Hepatitis B/inmunología , Antígenos de Superficie de la Hepatitis B/análisis , Hepatitis D/complicaciones , Humanos , Persona de Mediana Edad , Proteínas RecombinantesAsunto(s)
Hepatitis D/epidemiología , Adulto , Portador Sano/epidemiología , Portador Sano/inmunología , Niño , Anticuerpos Antihepatitis/análisis , Antígenos de Superficie de la Hepatitis B/análisis , Hepatitis D/inmunología , Virus de la Hepatitis Delta/inmunología , Humanos , Prevalencia , U.R.S.S./epidemiologíaRESUMEN
The Soviet leukocytic alpha 2-interferon obtained by gene engineering was assessed (according to the clinical and biochemical findings) for the therapeutic efficacy in acute viral hepatitis B. The drug was injected intramuscularly to patients with grave and medium-grave hepatitis during 10 days. The treatment was instituted within the first 1-5 days of jaundice. The patients with medium-grave acute viral hepatitis B manifested a beneficial therapeutic effect of alpha 2-interferon obtained by gene engineering as did the patients with the grave disease pattern before they developed the signs of liver encephalopathy.
